Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

A non-purine selective inhibitor of xanthine oxidase (XO) in prevention of Tumour Lysis Syndrome (TLS)

Present development stage: Pediatric Clinical Phase I/II

Febuxostat (Adenuric®) is a potent, non-purine selective inhibitor of xanthine oxidase (XO), approved in EU through a centralized procedure in April 2008 with the following indication: “treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including history, or presence of tophus and/or gouty arthritis)”. After completing the development in adults as preventive treatment of the Tumour Lysis Syndrome, in 2015 Febuxostat obtained the approval in Europe for the “prevention/treatment of the Tumour Lysis Syndrome in adult patients with haematological neoplasia treated with chemotherapy”. Currently, the clinical phase I/II FLORET is ongoing for the same indication in the paediatric population.

Therapeutic Areas


Discover all of Menarini's products marketed in Italy.




Advanced Technology


The Menarini Group


Discover the leading Italian pharmaceutical company in the world.


Quality first


Quality: point of departure and arrival for our drugs.